Results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab for multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma. Daratumumab is a novel therapeutic human CD38 monoclonal antibody.

Year of Production:
Running Time:
Color/Sound:

2015
2.00
Color/Sound

Comments are closed.